“Resuscitation” of marginal liver allografts for transplantation with machine perfusion technology  by Graham, Jay A. & Guarrera, James V.
Frontiers in Liver Transplantation‘‘Resuscitation’’ of marginal liver allografts for transplantation
with machine perfusion technology
Jay A. Graham, James V. Guarrera⇑
Center for Liver Disease and Transplantation, Department of Surgery, Columbia University College of Physicians and Surgeons and New York
Presbyterian Hospital, New York, NY 10032, USASummary
As the rate of medically suitable donors remains relatively static
worldwide, clinicians have looked to novel methods to meet the
ever-growing demand of the liver transplant waiting lists world-
wide. Accordingly, the transplant community has explored many
strategies to offset this deﬁcit. Advances in technology that target
the ex vivo ‘‘preservation’’ period may help increase the donor
pool by augmenting the utilization and improving the outcomes
of marginal livers. Novel ex vivo techniques such as hypothermic,
normothermic, and subnormothermic machine perfusion may be
useful to ‘‘resuscitate’’ marginal organs by reducing ischemia/
reperfusion injury. Moreover, other preservation techniques such
as oxygen persufﬂation are explored as they may also have a role
in improving function of ‘‘marginal’’ liver allografts. Currently,
marginal livers are frequently discarded or can relegate the
patient to early allograft dysfunction and primary non-function.
Bench to bedside advances are rapidly emerging and hold prom-
ise for expanding liver transplantation access and improving
outcomes.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
The advent of successful liver transplantation (LT) by Starzl et al.
shifted the paradigm of hepatic failure as a terminal illness into a
triumph of long-term meaningful survival [1,2]. However, the
overwhelming success of LT has created a new dilemma in which
the organ supply cannot meet the demand for LT. While there are
approximately 6000 liver transplants performed each year in the
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(J.V. Guarrera).United States, there are more than 11,000 patients added to the
waiting list every year [3]. As such, waitlist mortality has become
a central issue for the liver transplant community.
Early efforts to correct this disparity centered on the use of
the MELD (model for end-stage liver disease) score based alloca-
tion. Interestingly, unlike end-stage renal disease, waitlist mor-
tality does not correlate with waiting list time for patients
with end-stage liver disease (ESLD) [4]. As such, the MELD score
served to identify the sickest patients who had the highest risk
of pre-transplant death and moved them to the ‘‘top of the list’’
[5].
Living donor liver transplantation (LDLT) has also arisen as a
means to confront the growing disparity between supply and
demand. The Adult-to-Adult Living Donor Liver Transplantation
Cohort Study (A2ALL), a North American consortium of transplant
centers, published excellent outcomes with LDLT [6]. This initial
report and forth coming validation helped promote living dona-
tion as a viable option for patients looking to minimize their
waitlist mortality risk [7]. However, LDLT while routine at many
centers has not and will probably never signiﬁcantly address the
supply and demand disparities due to issues of donor safety and
morbidity; not to mention the increased technical demands of
LDLT.
Ten to ﬁfteen percent of patients on the waiting list die annu-
ally before a liver graft becomes available [8,9]. An effort to
reduce wait list mortality has included exploring other methods
to improve access to transplant and reduce waiting time. There
are also many patients who are underserved by the MELD score,
and would beneﬁt from early transplantation or will not achieve
a high enough MELD score to receive an organ offer in regions
with donor scarcity. Unfortunately, this can usually only be
accomplished with the use of so-called ‘‘marginal grafts’’ or LDLT.
Expanding the donor pool by utilizing ‘‘marginal’’ grafts,
which include extended criteria donor (ECD) and donor after car-
diac death (DCD) livers appears to be the most logical answer.
However, expansion of the donor pool with organs that have a
higher failure rate seems irresponsible without concomitantly
searching for novel interventions to improve the function of these
ECD/DCD livers.
Our center has reported that transplantation of ECD livers
improved patient survival and showed that the use of these
marginal liver grafts maximizes donor utilization and increased
access to liver transplantation [10]. Barshes et al. also14 vol. 61 j 418–431
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demonstrated that using ECD livers as deﬁned by the New York
State Department of Health Workgroup signiﬁcantly reduced
waiting list mortality [11,12]. As such, there has been a
shift toward greater use of ECD livers. However, this utilization
is not without problems and may lend itself to adverse
outcomes.
The use of other types of livers, speciﬁcally DCD allografts
by aggressive centers have also been proffered as a means to
reduce waitlist mortality. However, recent trends showed pro-
gressively decreased utilization of DCD livers due to higher rates
of ischemic cholangiopathy and graft loss [13]. The expanded
use of marginal livers has also prompted the transplant commu-
nity to confront the issue of preservation related ischemia/
reperfusion injury (IRI). Techniques to ameliorate the clini-
cal adverse effects of IRI have become a focus of research
worldwide.
In an excellent review, Peralta et al. make the case that the
consequences of the bimodal nature of IRI is perhaps the most
important factor that inﬂuences graft dysfunction after trans-
plantation [14]. Initially, the resultant lack of a terminal electron
depot due to hypoxia leads to disruption of aerobic respiration
and subsequent cellular metabolic disarray. Reperfusion further
damages the organ via oxygen free radicalization and sheer stress
injury to ischemically challenged sinusoidal endothelial cells. Van
Golen et al. also illustrate the inciting events that evoke an
inﬂammatory cascade in organs subject to IRI [15]. At the hepa-
tocellular level, deprivation of oxygen promotes the release of
damage associated molecular patterns (DAMPs) like HMGB-1,
which leads to activation of Kupffer and dendritic cells. Reperfu-
sion exacerbates IRI when reﬂow facilitates contact between
these antigen presenting cells (APCs) and primed T-cells, neutro-
phils, and monocytes. This concept of the inﬂammatory response
in IRI is theorized to represent a major antagonist toward
improved outcomes for transplanted livers. Attenuation of this
deleterious milieu and ‘‘resuscitation’’ of these grafts with the
use of ex vivo techniques will be the focus of this review [16–18].
Key Points
• Marginal or Extended Criteria Donor (ECD) Livers 
represent a pool of organs in which recipient outcomes 
may be suboptimal. As the waiting lists for liver 
transplantation grow worldwide, increasing reliance on 
these allografts is crucial 
• Liver preservation has been essentially unchanged for 
more than two decades. Exciting novel work in the area 
of ex vivo techniques such as machine preservation 
and persufflation of the liver has gained attention of the 
liver transplant community and has recently moved into 
the clinical setting
• Ex-vivo techniques may “resuscitate” damaged or 
marginal liver allografts by diminishing preservation 
related ischemia/reperfusion injury (IRI) thereby 
improving early allograft function and reducing 
transplant complications 
• Machine perfusion is a platform on which ex-vivo 
therapies such as advanced pharmacologic, stem cell 
or genetic interventions may be developedJournal of Hepatology 201Marginal livers provide an excellent template from which to
study the efﬁcacy of preservation techniques
What constitutes a marginal or poor quality liver graft?
Introduced by Renz et al., [10] the term extended donor criteria
(EDC) codiﬁed utilization of deﬁned types of marginal liver grafts
to reduced waitlist mortality. These EDC (= ECD) livers were fre-
quently considered unusable based on retrospective data indicat-
ing poor outcomes after transplantation [19]. The novelty in this
study was that it highlighted the concept that waitlist mortality
could not be thought of in the abstract and that it was a central
variable in the analysis of outcomes. Considering that waitlist
mortality is an endpoint in survival analysis, ECD donors may
offer the possibility of slightly reduced graft survival, but the
patient survival is nevertheless improved. ECD livers were
deﬁned from donor characteristics that were previously identi-
ﬁed to lead to a higher risk of poor early graft function (PEGF)
or primary non-function (PNF) which included: age >65 years,
[20,21], serum sodium >155 mEq/dl [22,23], macrosteatosis
>40% [24,25], cold ischemic time (CIT) >12-h [26], split-liver
grafts [27], DCD grafts [28], positive infectious serology, and
donors with Centers for Disease Control and Prevention (CDC)
high-risk behavior. However, as the ECD livers became more
widely utilized, many prominent centers began to deﬁne these
marginal livers in some variation and extol upon their equivocal
outcomes in select patient groups.
At the University of California Los Angeles (UCLA) semanti-
cally using the more accepted term ECD instead of EDC, donors
were characterized as having an age >50, donor hospital stay
>5 days, serum sodium >155 mEq, CIT >12-h and a warm ische-
mia time (WIT) >40 min [29]. Interestingly, in their experience
the usage of livers with 2 or fewer ECD characteristics yielded
one-year survival of 77–87% [30]. At the University of Indiana
these criteria were broadened to include BMI >34.9, a maximum
alanine aminotransferase (AST)/aspartate aminotransferase (ALT)
>500 and a maximum bilirubin >2.0 mg/dl at which time they
demonstrated comparable 2-year 78–83% overall survival
between ECDs and standard criteria donors (SCD) [31].
Historically, these deﬁnitions and various adaptions were
used to establish standards for what was an innovative use for
these marginal livers. However, given that there is no universal
deﬁnition for an ECD liver, transplant centers are constantly tai-
loring and altering this classiﬁcation as their experience dictates.
As such, it has often relegated analysis to single center practice or
made comparison among multiple centers difﬁcult. Some gener-
ally agreed upon donor criteria, which impart risk of adverse reci-
pient outcomes are found in Table 1.
The donor risk index has been used to deﬁne marginality in liver
transplantation
The introduction of the donor risk index (DRI) by Feng et al. has
established that there is an increased relative risk of early
allograft dysfunction and decrease graft survival with the use of
marginal livers [32]. The six donor characteristics found to be sig-
niﬁcant in multivariate analysis that make up the DRI are: age,
DCD, split/partial status, donor race, height, and cause of brain
death. Of note, the omission of steatosis from the DRI is a signif-
icant problem noted by many clinicians. Nevertheless, validated
by the study of a large European cohort, the DRI was found to4 vol. 61 j 418–431 419
Table1. Donor characteristics which impart risk of adverse recipient outcomes.
Elderly donors (>65 yr) More susceptible to ischemic endothelial injury
Decreased ATP availability on reperfusion
Less tolerant of prolonged cold ischemia
May have decreased synthetic function and regenerative capacity
Underlying liver histopathology Macrosteatosis → predisposes to early allograft dysfunction and primary non-function
Ischemic changes/necrosis
Significant alcohol abuse → steatohepatitis
Hepatitis B and C activity/portal inflammation
Fibrosis → may be associated with hepatitis C or alcohol abuse and may affect long-term outcomes
Ischemia associated with donor 
injury
Donation after cardiac death → frequently profound ischemia injury
High-dose vasopressors
Prolonged or uncorrected hypoxemia or acidosis
Biochemical changes Hypernatremia
Rising transaminases or bilirubin
Frontiers in Liver Transplantationbe the strongest predictor of graft functional outcomes [33].
However, examination of national patterns demonstrates an
increasing usage of livers with higher DRI scores due to the utili-
zation of grafts from older donors and DCDs in an attempt to curb
waitlist mortality [34].
Some recent data demonstrates that the current strategy of
offering these livers to patients with lower MELD scores may be
counter-productive [35]. As such, the transplant community is
at a crossroads as there are clearly patients with decompensation
that are underserved by the current MELD classiﬁcation system
[36]. One solution to this predicament that shows promise, is to
reduce the IRI insult seen with many marginal livers with the
evolving technology of hypothermic machine perfusion (HMP),
subnormothermic machine perfusion (SMP), normothermic
machine perfusion (NMP), and PSF (persufﬂation).Long cold ischemic times may also lead to a poorer quality graft due
to derangements in metabolism
Livers subjected to increased CITs are considered marginal grafts
due to the obviously heightened risk of PEGF. In trying to explain
the degradation of graft function with prolonged CITs, the study
of mitochondrial function moved to the forefront after a series
of experiments expounded on their role in promoting metabolic
and cellular disarray. It was well accepted that ECD/DCD livers
are more susceptible to cold preservation injury, speciﬁcally with
regard to the disruption of oxidative phosphorylation and the
possibility of reversing the destabilizing effects. Studying the
mitochondrial respiratory function, Kim et al. demonstrated that
there was a gradual, but pronounced dysfunction in the homog-
enate of rat livers that underwent extended cold storage (CS)
[37]. Interestingly, this poorer mitochondrial function was found
to be abrogated in HMP of rat livers up to 48 h [38]. As such, neg-
ative effects on the electron transport chain (ETC) were thought
to lead to the cellular deterioration seen in prolonged CS.
Classically revered as the sine qua non of energy metabolism,
the ETC couples adenosine triphosphate (ATP) synthesis to oxy-
gen uptake and allows energy production through the mitochon-
dria membrane to the rest of the cell. Mitochondrial energy
derangement leads to severe implications in cellular and organ
function if the injuries are widespread. The loss of ATP homeosta-
sis in CS livers has been associated with metabolic and structural
changes that can lead to irreversible hepatic parenchymal injury
and PEGF [39]. While, the mechanisms are not completely420 Journal of Hepatology 201understood, depletion of mitochondrial ATP can lead to profound
consequences that include hepatocyte ischemia and necrosis. In
vitro experiments have shown that ATP diminution causes open-
ing of transmembrane gated proteins on the mitochondrial sur-
face responsible for maintaining a membrane potential. Termed
the membrane permeability transition (MPT) pores, the lack of
ATP severely impacts their functionality and can ultimately trig-
ger cell death through apoptotic pathways [40].
One hypothesis to explain this mitochondrial uncoupling of
ATP synthesis and oxygen uptake in the hepatocyte was
expounded upon after an elevated presence of fatty acids was
noticed to be associated with this dysregulation. Free fatty acids
accumulate in preserved livers and thereby increase oxygen con-
sumption at the expense of a decrease in the content ATP [41].
Importantly, this effect was shown to be countered by short term
oxygenated perfusion in vitro rodent models [42].
Steatotic livers exhibit impaired ATP synthesis from disruption of the
ETC and increased generation of reactive oxygen substances through
lipid peroxidation
Steatotic livers are marginal allografts with high levels of PNF and
PEGF when implanted [43]. As a result, many of these livers are
discarded, especially if the biopsy reveals macrosteatosis >30–
40% [44]. Interestingly, the poorer outcomes associated with
transplantation of steatotic livers are theorized to be multi-focal,
but are centered around impairment of the ETC and ATP synthesis
[45]. It is hypothesized that excessive cytoplasmic fatty acids
may lead to increased lipoperoxidation yielding more free radi-
cals [46]. This can in turn lead to damage of the cellular architec-
ture and inappropriate Kupffer cell activation with concomitant
pro-inﬂammatory upregulation [47]. The promise of HMP is that
it may counter these deleterious effects in the short-term and
lead to better long-term outcomes.Hypothermic machine perfusion
The early history of liver hypothermic perfusion techniques and its
evolution
In 1956, Goodrich et al. established that WITs as short as 30 min
could render the liver untransplantable [48]. Recognizing the lim-
itations imposed by the profound effects of ischemia, Starzl et al.4 vol. 61 j 418–431
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were the ﬁrst to introduce the concept of hypothermic perfusion
as a method to preserve the liver for transplantation by in situ
cannulation and ﬂushing of the liver [49].
It was in this spirit that the idea of machine perfusion was
conceived, when in 1963 using an adaption of the heart-lung
machine, cadaveric in situ hypothermic perfusion was introduced
[50]. While these methods ultimately cooled the liver, clinicians
were still hampered by the relatively short allowance of 2–3 h
of CIT before transplantation. In an attempt to allow for extended
CITs, in 1967 the concept of extracorporeal/ex vivo HMP was pre-
sented in which 24-h of hypothermic perfusion was demon-
strated in canines [51]. Interestingly, this presentation was not
considered proof of principle as the donor grafts were implanted
into the neck and the canine remained unhepatectomized. Never-
theless, this publication was the ﬁrst concept of using HMP for
liver transplantation. Shortly thereafter in 1968, Brettschneider
et al. used HMP with homologous blood perfusate and hyperbaric
oxygen to push preservation times to 8 h with subsequent canine
orthotopic transplantation [52].
Others studies would follow that began to show a crude
reﬁnement of this technique, however, they would be short-lived
and never reach clinical utilization. The additional cost and com-
plexity of the bulky HMP equipment would be one reason why
this nascent technology fell out of favor with clinicians [53].
Moreover, the expanding role and simplicity of static cold preser-
vation solutions that could seemingly protect the liver from
ischemia and reperfusion injury gained mass appeal. The advent
of Collins/Eurocollins solutions and later University of Wisconsin
(UW) solution, gave transplant practitioners a less expensive,
reproducible, and simpler means of preserving livers for trans-
plantation [54,55]. As such, research regarding liver HMP would
slow for some time. However, the early 1990’s would bring about
an interest in renal HMP due to the problem of high rates of
delayed graft function (DGF) in ECD kidney transplantation. This
work has also led to a renewed interest in liver HMP given the
greater use of ECD liver grafts.
Metabolic preservation of hypothermic machine perfused livers is
profound
HMP ensures homogeneity in the continuous supply of metabolic
substrates and antioxidants to the liver parenchyma during the
ex vivo period. Aerobic respiration is reduced by hypothermia
but does not entirely cease. Provision of high-energy metabolic
substrate reduces cellular insults typically seen with reperfusion.
HMP not only augments the scavenger role of the antioxidants,
but also provides a dilutional and washout effect, thereby pre-
venting the accumulation of toxic metabolites and waste prod-
ucts from direct endothelial and parenchymal contact.
Kamada et al. described using a continuous pulsatile perfusion
technique with ﬂuorocarbons in rats to prolong CITs [56]. Not
long thereafter, HMP in a larger animal model was shown to
lengthen storage times [57]. For the next two decades, research-
ers would use these models and others like them to uncover the
pathways that became deranged after liver procurement.
Hypothermic machine perfusion could attenuate the deregulation of
the oxidative phosphorylation pathway
HMP can lead to abatement of ATP depletion in ischemic livers by
sustaining oxidative phosphorylation. As such, comparing ATPJournal of Hepatology 201concentration in CS and HMP, Dutkowski et al. demonstrated that
HMP livers provided a greater ATP content at 10-h as compared
to CS livers [58]. A similar study performed years later supple-
mented the understanding of hypothermic perfusion and its
impact on cellular viability after prolonged ischemic times. As
such, a brief 3-h period of HMP after a 10-h CIT demonstrated no
changes in lipid peroxidation, energy charge or increases in cellular
injury markers, which included lactate dehydrogenase (LDH) or
caspase activity when compared to freshly resected livers [59].
In order to mimic marginal liver grafts and assess the effect on
metabolic function, Stegemann et al. cold stored rat livers for 22-
h before a brief warm ischemic challenge [60]. Subjected to 90-
min of HMP, these livers demonstrated an increased energy
charge (EC) of ATP phosphorylation as calculated according to
Atkinson et al. (EC = (ATP + 1/2ADP)/(ATP + ADP + AMP)) [61].
Moreover, as compared to the 22-h CS livers, the HMP livers
showed improved vascular resistance, and increased bile produc-
tion, ammonia clearance and oxygen utilization.
While the mechanisms of this ATP loading remain obscure,
perhaps the lower energy demand of a cooled liver and the con-
tinuous supply of oxygen may favor this positive ATP balance. As
such, this provided the early evidence that HMP technology could
lessen preservation injury.
Reactive oxygen substances accumulate during ischemia can also
lead to signiﬁcant hepatocyte toxicity that can be ameliorated by
hypothermic machine perfusion
Generally, the mitochondria redox reactions generate relatively
few reactive oxygen substances (ROS) as the electrons from nic-
otinamide adenine dinucleotide (NADH) oxidation are used to
create water (H2O) from oxygen (O2) and hydrogen (H+) [62].
Moreover, anti-oxidant defenses are thought to play a crucial role
in the reductive capacity of these protective cellular mechanisms
[63]. Nevertheless, even under homeostatic conditions low level
of electrons escape from the downstream redox proteins in the
ETC and can create ROS [64].
Under stressful conditions like IRI this process can be exacer-
bated as the ETC is highly reduced and there is a relative lack of
oxygen resulting in the unintended transfer of electrons and cre-
ation of ROS [65]. Importantly, Dutkowski et al. would provide
further evidence that HMP could protect the liver from these
ROS; notably there was a decrease in glutathione depletion and
superoxide anion release in machine perfused rodent livers as
compared to their CS counterparts after 10-h [66]. This is partic-
ularly important as it is known that ROS may incite oxidative
injury and impact cell viability especially in energy depleted
hepatocytes [67]. From these collective experiments it has been
deduced that HMP can provide a two-pronged approach by fend-
ing off oxygen radical formation and increase radical scavenger
activity through glutathione salvage.
Restoration ATP synthesis in steatotic livers to prevent ROS lipid
peroxidation in hypothermic machine perfused livers
A study by Bessems et al. demonstrated that livers from methio-
nine-choline fed rats resulting in 30–60% steatosis were better
preserved if they underwent HMP as opposed to CS [68]. As such,
ammonia clearance, ATP levels, urea, and bile production were
higher in these steatotic livers that had 24-h of HMP as compared
to standard CS.4 vol. 61 j 418–431 421
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The clinical application of hypothermic machine perfusion in livers
shows the possibility of changing the landscape of marginal liver
utilization
Although, successful LT has being reported after CITs approaching
24-h [69], it is well known that the liver functionality declines
after 12-h of cold ischemia and even earlier in marginal livers
[70]. For this reason, the extension of HMP into clinical LT has
ﬁnally gained traction. Moreover, its efﬁcacious use in other
organ systems has further spurred the application and develop-
ment of this technology.
The push of HMP has really been in the clinical experience in
kidney transplantation. Over a decade ago, HMP was initially
shown to be associated with improved early and long-term renal
function as compared to standard CS [71]. More recently, these
results were validated in a randomized control trial study that
demonstrated an adjusted odds ratio of 0.57 comparing HMP to
CS for reduction of DGF and overall graft survival at one year
[72]. The three year assessment continued to demonstrate this
improved graft survival for HMP kidneys, especially in those from
donors after brain death (DBD) [73]. This success story has fur-
ther fostered the translational aspect of liver HMP as it enters
the clinical setting in an attempted rehabilitative effort of poorer
quality livers.
Hypothermic machine perfusion of DCD livers offers protection from
IRI cellular injury
While DCD donation in kidney transplantation has yielded posi-
tive returns, LT of these organs can be fraught with unaccept-
ably high rates of ischemic cholangiopathy and PEGF leading
to diminished long-term graft survival. The outcomes associated
with organs procured from DCD donors are due to prolonged
WITs and low pulsatile ﬂow as the cardiac output begins to pro-
foundly lessen until asystole. As such, DCD livers encapsulate for
many centers the very deﬁnition of a ‘‘marginal’’ liver and are
accordingly frequently declined by most centers. Safe expanded
use of these livers could represent a signiﬁcant viable donor
pool, thereby alleviating some of the burden of waitlist
mortality.
Beginning at the turn of this century, efforts to resuscitate
these livers were centered on the use of HMP in the laboratory.
In DCD rodent models, the rehabilitatory effects of HMP could
be seen in livers subjected to 30-min of WIT [74,75]. As such,
reduction of portal vein pressures and LDH levels were seen after
10-h of perfusion in HMP livers as compared to CS. Likewise, CS
livers had larger patchy areas lacking ﬂow as measured by the
dearth of ﬂuorescein isothiocyanate-labeled albumin, in contrast
to the HMP livers that had more normal ﬂow homogeneity.
Dutkowski et al. further advanced the notion that HMP could
resuscitate marginal DCD livers with only 1-h of perfusion after
45-min of WIT [76]. Comparing 2 groups of rat livers with 45-
min of WIT followed by either 5-h of CS vs. 5-h of CS and then
1-h of HMP, the later arm was found to have signiﬁcantly reduced
necrosis after 3-h of normothermic reperfusion. Moreover, only
1-h of HMP after CS seemed to reduce hepatocellular ischemia
as seen by decreased AST release and lactate levels in the reper-
fused livers. Interestingly, livers that underwent HMP for an hour
also had less oxygen uptake than non-HMP livers after reperfu-
sion, which in theory could mitigate exposure to oxygen and pos-
sible free radical injury.422 Journal of Hepatology 201In a recently published pivotal study, Dutkowski et al. reaf-
ﬁrms the importance of oxygenated perfusion for DCD livers
[77]. Perfusing through the portal vein using hypothermic oxy-
genated perfusion (HOPE), another moniker for HMP, oxygen is
the limiting factor in reduction of the NADH and a safeguard of
mitochondria integrity. Contrastingly, replacing oxygen with
nitrogen in this system allows for a highly reduced ETC, Kupffer
cell activation, and mitochondrial injury. While these pathways
represent a signiﬁcant obstacle in the successful use of ECD/
DCD livers, recently there has also been a renewed interest in
the immunologic up-regulation due to warm ischemia.
HMP for a brief period before subsequent CS was found to
decrease the release of intracellular adhesion molecule 1
(ICAM-1) and major histocompatibility complex (MHC) class II
HLA antigens [78]. Important in facilitating leukocyte endothelial
transmembrane migration, ICAM-1 can promote early rejection,
while MHC class II overexpression in mismatched donor-recipi-
ent pairs may augment an immunological response [79,80]. As
such, short term HMP may also protect and ultimately allow
immunologic recovery of quiescence in DCD livers. However,
while this study has been limited, ongoing work may verify this
beneﬁcial mechanism of HMP to marginal livers.
In recent work Schlegel et al. also described a protective effect
on the rodent biliary system using HMP in DCD grafts that under-
went transplantation [81]. Expectedly, perfusion with the HOPE
system for only 60-min after 4-h of CS decreased the parameters
of hepatocellular injury, lowered the level of DAMP signaling
(HMGB-1) and tamped down immunogenic upregulation (CD68,
CD4+ T cells). 4-weeks after transplantation, bilirubin levels in
these DCD livers perfused with HOPE had a mean bilirubin of
9 lmol/L, while those livers that solely underwent 4-h of CS
had a mean bilirubin of 15 lmol/L (p = 0.08). While this parame-
ter did not rise to the level of statistical signiﬁcance, microscopy
demonstrated signiﬁcant cholangiopathic proliferation and ﬁbro-
sis (Sirius red, a-SMA, CK-19) in the untreated DCD liver group as
compared to those that underwent HMP.
The realization of hypothermic machine perfusion in transplantation
Notwithstanding the interesting ﬁndings associated with these
in vitro and small animal studies, discovery as it would pertain
to liver recovery and reconditioning largely found its place in
the porcine model. Studies by Mastuno and Uchiymama would
provide support for the use of swine livers to study HMP and
rehabilitation because of technical feasibility of both perfusion
and transplantation [82,83]. In 2009 de Rougemont et al. were
amongst the ﬁrst to show that a short run of HMP could rescue
pigs from certain death when undergoing DCD transplantation
[84].
The early results from human trials with hypothermic machine
perfusion highlight the future possibilities
Earlier work in animal and human discard liver models facilitated
the translation of HMP into a human clinical trial for the ﬁrst time
by our group [85]. Guarrera et al. at Columbia University became
the ﬁrst investigator worldwide to use HMP on human livers that
were transplanted successfully [86]. The purpose of the initial
trial was to assess its reliability and safety of liver HMP in a
clinical setting. A modiﬁed Medtronic (Minneapolis, MN) non-
pulsatile pump and Vasosol solution was used to perfuse4 vol. 61 j 418–431
Fig. 1. A representative liver allograft undergoing HMP from the Columbia University Medical Center Liver HMP Clinical Trial (ClinicalTrials.gov: NCT01274520). PV,
Portal vein; Ao, Aorta; CHA, Common hepatic artery.
JOURNAL OF HEPATOLOGY20 transplants in a case-controlled clinical trial of liver HMP in
humans. HMP was associated with decrease in early allograft
dysfunction (as deﬁned by the Clinical Trials in Organ Transplan-
tation Study Group) compared to those in CS control group [87].
In addition, HMP livers exhibited lowered IRI markers, peak
transaminases, improved renal function, and shorter hospital
length of stay. A representative liver allograft undergoing HMP
from our trial is shown in Fig. 1.
Immunohistochemistry and RT-PCR analysis of livers in this
phase I clinical trial was assessed for the post reperfusion expres-
sion of pro-inﬂammatory cytokines and adhesion molecules. As
would be predicted, the livers from the HMP arm showed atten-
uated chemotactic cytokine over-expression and thereby pre-
vented leukocyte recruitment and Kupffer cell activation along
the donor endothelium [88]. The cellular and cytokine injuries
speciﬁc to the liver are succinctly summarized in Fig. 2. In addi-
tion, efﬂuent analysis during HMP showed a reduction in these
acute phase reactants. This reduction was also shown to be
sustained and progressive on the HMP device [89].
Of note, a US Health Resources and Services Administration–
sponsored trial using HMP to preserve ECD livers has been
completed at our center with promising results including
shorter length of stay, better early liver and renal function andJournal of Hepatology 201signiﬁcantly less biliary complications. [16]. More recently, Dut-
kowski et al. advanced the applicability of HMP by using an
ECOPS device (Organ Assist) to perfuse 8 DCD donor livers
(Maastricht category 3) prior to transplantation [90]. After a strict
10-min ‘‘no-touch’’ period following asystole, using a double
balloon catheter in the iliac artery the donor organs were ﬂushed
and retrieved with a functional mean WIT of 31-min. The liver
was subsequently placed on the HOPE system and transplanted
after 1–2 h of reperfusion at 10 C. Importantly, hepatic function
was comparable with DBD donor livers after transplantation and
there was no evidence of biliary cholangiopathy on MRCP. This
study represents the ﬁrst foray into the human clinical use
of HMP for DCD livers and dramatically raises the bar for the
possibilities and utility of this technology.
The human discard liver HMP experience would reinforce the
beneﬁts seen in the clinical setting
The arrival and success of these clinical human trials would
provide the backdrop for adjunctive studies that would test the
limits of the applicability of HMP technology. Generally reﬂecting
the poorest quality livers because of severe macrosteatosis or
DCD status, livers that were unable to be allocated were used4 vol. 61 j 418–431 423
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HMP even in the extreme. Vekemans et al. applied HMP to 12
human discard livers with oxygenated ﬂow-limited perfusate
through the portal vein (3 mmHg) and common hepatic artery
(20 mmHg) [91]. After 4-h of HMP, these livers displayed
improved hepatocellular injury metrics (AST, LDH) during
rewarming as compared to a CS cohort of discarded livers. Inves-
tigators have also promoted the use of HMP as a means to indi-
cate the liver quality prior to transplantation. Again using a
human discard model, Monbaliu et al. dichotomized discarded
livers into two groups; not transplantable livers (macrosteatosis
>30%, toxic hepatitis with cholestatic appearance and alcoholic
steatohepatitis) and potentially transplantable livers (allocation
problems) [92]. Not unexpectedly, perfusate from the non-trans-
plantable group had higher levels of AST and LDH despite HMP. In
this way, HMP may allow for efﬁcient graft evaluation as differ-
ences in these biomarkers became readily apparent as early as
30-min after the commencement of HMP.
Perfusates for machine perfusion
Collins solution, blood components or UW solution were initially
used in earlier liver HMP studies. The optimal perfusate has not
yet been determined and is a topic of debate. Our clinical liver
HMP trials have all used Vasosol with promising results. Vaso-
sol is based on Belzer’s Machine Perfusate which is utilized for
Renal HMP (KPS-1, Organ Recovery Systems, Itasca, IL, USA),
Vasosol is enhanced with alpha-ketoglutarate as an energy sub-
strate and mitochondrial stabilizer, nitroglycerine and L-arginine
as a nitric oxide precursor, N-acetylcysteine as a glutathione pre-
cursor, and both nitroglycerin and prostaglandin E1 as vasodila-
tors. Our lab is currently investigating perfusates and has
shown beneﬁts of Vasosol over Belzer MPS™ in a rodent model
of HMP. We also saw a beneﬁt in adding alpha tocopherol424 Journal of Hepatology 201(Vitamin E) to Vasosol to further enhance antioxidant properties
(unpublished data, in submission).
Speciﬁc perfusate requirements will also vary based on the
temperature of machine perfusion. Normothermic perfusion
requires advanced metabolic support since the organ is fully met-
abolically active. NMP has typically utilized diluted blood based
perfusates and more recently the acellular ‘‘Steen Solution’’.
Polysol™, a balanced solution enriched with various amino
acids, vitamins, antioxidants (alpha-tocopherol, ascorbic acid
and glutathione), impermeants (rafﬁnose and trehalose), and
other metabolites (glucose) [93]. In rodent studies, HMP livers
pumped for 24 h in Polysol™ demonstrated less cellular damage
as indicated by assessing and noting the lessened serum spillage
of liver functional enzymes. Polysol™ was then evaluated in
rodent livers subjected to a pre-HMP 30 min WIT to mimic a
DCD organ [94]. After 24-h of perfusion, the livers were reper-
fused with Krebes-Henseleit buffer. Again there was less AST
and ALT leakage when comparing HMP-Polysol™ livers to CS or
UW-livers. Moreover, there was less readily apparent vacuoliza-
tion, sinusoidal edema or necrosis seen in the HMP-Polysol™
organs.Normothermic machine perfusion
Is the ﬁeld of liver preservation warming up?
More recently, the concept of hypothermia as a necessary entity
to decrease the metabolic requirements of the liver has been
challenged. Normothermic preservation may lead to sustained
viability, improved hemodynamics and attenuate ischemic injury
in marginal livers [17]. An ex vivo liver perfusion system was
initial used to investigate NMP [95]. These livers were reperfused
with porcine blood at 32 C or 37 C after a period of cold4 vol. 61 j 418–431
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preservation with varying results. Friend et al. would also be
amongst the ﬁrst to describe NMP and its beneﬁts over standard
CS as measured by preservation of ALT and enhanced Factor V
production [96]. Minor et al. demonstrated the rewarming of por-
cine liver grafts up to 20 C even over a short course resulted in
reduced enzymatic leakage, lipid peroxidation, and histologic
injury [97]. However, it may be better to never cool the liver
and continue NMP, thereby avoiding a hypothermic period that
may have a deleterious effect on the graft [98].
In another study, the blood based perfusate was rewarmed to
37 C and perfused through discarded human livers for 6-h [99].
This study represents the ﬁrst foray of NMP into studying human
grafts and challenges that were met. Importantly, these livers
demonstrated both increased biochemical viability and decreased
hepatocellular injury. Using this whole blood perfusate at 39 C,
Imber et al. would also show that porcine livers were able to
maintain normal bile production for 20-h with supplementation
with taurocholate [100]. Glucose metabolism and galactose
clearance were also corrected with 24-h of NMP as compared
to CS [101]. Moreover, using this model, NMP for an astonishing
20-h after 40-min of WIT signiﬁcantly increased post-transplant
survival [102].
Injury from warm ischemia in DCD livers may be attenuated using
normothermic machine perfusion
St Peter et al. also demonstrated that porcine DCD livers with 60-
min of WIT that underwent NMP faired signiﬁcantly better than
standard CS [103]. Notably, ALT levels were markedly lower in
NMP livers than CS controls after reperfusion, suggesting a much
lower degree of hepatocyte cytolysis. Moreover, histological spec-
imens from the livers in the CS arm conﬁrmed the presence of
gross hepatocellular necrosis and sinusoidal hemorrhage while
the NMP were relatively sparred. Accordingly, they suggest that
DCD livers maybe rehabilitated after a course of NMP. In another
animal model designed to mimic logistics of actual procurement
practices, rat livers were exposed to 45-min of WIT followed by a
2-h period of CS to mimic the initial procurement and transport
logistical period [104]. These livers were then placed on the
NMP circuit for 4-h and then transplanted with resultant 100%
1-month survival.
Transferring DCD livers after 60-min of WIT immediately to
the NMP circuit may be more beneﬁcial than cooling the liver
for 1-h in CS solution prior to NMP (CS + NMP) [105]. While
CS + NMP livers showed similar synthetic and biliary production
characteristics as compared to NMP alone livers, hepatocellular
damage as measured by AST, beta-galactosidase (Kupffer cell
injury), and hyaluronic acid (endothelial cell impairment) was
more apparent. As such, NMP may attenuate the CS injury to
the endothelial cell as described by Ikeda et al. transplanted
rodent livers [106].
In an important paper by Schön et al., the term normothermic
extracorporeal perfusion (NELP) was coined to describe NMP
[107]. Again utilizing whole blood mixed with an isotonic solu-
tion, donor livers were perfused with the NELP circuit at 37 C.
Importantly, NELP allowed for survival in all transplanted grafts
and facilitated recovery of DCD livers exposed to 1-h of WIT. Tol-
boom et al. also similarly showed the rehabilitatory properties of
NMP when DCD Lewis rat livers exposed to 1-h of WIT had a 92%
4-week survival if they were placed on the NELP circuit for 6-h
prior to implantation, while non-NELP livers all died withinJournal of Hepatology 20112-h [108]. This experience was repeated, albeit with a more
extreme time frame, when Butler et al. placed porcine livers on
the NELP circuit for 72-h [100,109]. While non-NELP livers
showed massive necrosis after 72-h, those undergoing NMP had
preserved architecture and synthetic function.
Ex vivo NMP in DCD porcine livers at 38 C may also facilitate
sustained oxygen extraction with normalized metabolism [110].
ATP is likewise restored to pre-ischemia levels despite WIT of
1-h with NMP after cardiac arrest in Yorkshire pigs [111]. During
the warm ischemic phase in DCD grafts, ATP can rapidly be
depleted [112]. As such, this extracorporeal NMP system with
porcine blood was able to reconstitute a more normal hepatic
milieu after only 4-h of perfusion.
Extracorporeal membrane oxygenation allows for in situ
normothermic perfusion of marginal livers
Initial reports of donation after prolonged extracorporeal mem-
brane oxygenation (ECMO) in otherwise standard criteria donors
lead to the consideration of an expanded role for this technology
[113,114]. Cannulating a major artery and vein, ECMO offers
in situ normothermic perfusion before procurement, which can
counter the disastrous effects of WIT after cardiac arrest. As such,
Rojas et al. began some of the ﬁrst experiments to assess the use
of ECMO in DCD swine with assessment of liver markers [115].
The appearance of this procedure in the clinical setting would
be rapid, when a combined group of practitioners at Michigan
and Wisconsin would report the use of ECMO in DCD donors
for kidney transplantation [116]. Following this report, Jiménez-
Galanes et al. would describe the ﬁrst prospective human study
of ECMO in uncontrolled DCD donors (n = 20) in liver transplan-
tation [117]. When compared to DBD LTs (n = 40), the one-year
graft survival was equivocal (87.5% vs. 80%), although 15% of
patients in the ECMO DCD arm would ultimately need to be
re-transplanted.
While this experience is rare in the United States due to exist-
ing donor laws, in Spain, family consent is not legally needed in
order to start ECMO in Maastricht 2 donors, in which death is
unpredictable [118]. Therefore the Spanish DCD practice largely
reﬂects the utilization of asystolic trauma victims that have
undergone unsuccessful resuscitation by the ﬁrst responders
and have had a 5-min of a ‘‘no-touch’’ period, after which time
the donor can be placed on the ECMO circuit. Generally the fem-
oral artery and vein are cannulated with supra-celiac occlusion
balloon placement [119]. Of note, due to the clinical nature of
these studies the WIT accrued is in situ, while the previous animal
models allow for WIT ex vivo. It is still unclear if these differences
in WIT can affect the liver with varied manifestations.
In a novel approach, Fondevila et al. used ECMO (termed nor-
mothermic extracorporeal membrane oxygenation or NECMO in
this manuscript) for 60-min after a sustained period of cardiac
arrest (90-min) in donor swine [120]. After NECMO, the livers
in this study either had CS or NMP; NECMO + NMP had decreased
pro-inﬂammatory markers, like IL-6, TNF, and vWF as compared
to the NECMO + CS group.
While the transplant community has not adopted the use of
this NMP in any clinical setting as of yet, it represents a new foray
into preservation and may ultimately yield important dividends
for optimizing marginal grafts. Moreover, NMP will likely facili-
tate an expanded scientiﬁc query into the best composition of
normothermic perfusate, given that whole blood components4 vol. 61 j 418–431 425
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have been used commonly and have signiﬁcant drawbacks. There
are also many technical concerns with NMP. If monitoring is
inadequate or the device fails there is rapid warm ischemic injury
to the allograft. There are also concerns around microbial con-
tamination and transmission to the recipient that needs to be fur-
ther addressed.Subnormothermic machine perfusion
Subnormothermic machine perfusion has also been explored as a
means to reconditioning marginal livers
More recently, SMP has been advocated as a possible alternative.
Olschewski et al. suggested that perfusion at 21 C for 6-h
through the portal vein of Wistar rat livers after a 1-h WIT
(DCD) was better than with temperatures of 4 C or 12 C [17].
To reenact in vivo reperfusion, all livers were then perfused at
37 C. Livers subjected to SMP at 21 C demonstrated reduced
portal pressures, better bile production, and decreased markers
of ischemia. In a porcine model, steatotic livers studied with
SMP maintained factor V and bile production comparable to nor-
mal livers [121].
Tolboom et al. also presented that SMP was beneﬁcial to
reconditioning transplanted rodent livers subjected to 1-h of
WIT after cardiac arrest [122]. However, while the cooler temper-
atures may reduce oxygen uptake in this experimental model, the
effect on the phenotypical expression of ischemia was a mixed
picture. Given the limited research on SMP, the use of this tech-
nique is unclear. Moreover, it is not known if promising results
reﬂect the positive effects of machine perfusion on the whole.Persufﬂation
The early validation of persufﬂation as a means for preservation
Remarkably, PSF started by accident in 1902 by Rudolf Magnus
when his liquid perfusate supplying a cat heart ran empty and
pressurized oxygen gas was drawn into the circuit [18]. To his
surprise, Dr. Magnus observed rhythmic pulsations for up to 9-
min after the reservoir ran dry. This was the beginning of PSF
and the ushering in of subsequent studies illustrating that gas-
eous oxygen perfusate could allow for contractility from over
an hour.
Extrapolating this concept to the liver, Fischer et al. initially
studied PSF in rat livers with retrograde oxygenated gas perfusion
of the hepatic veins and puncturing the liver with ‘‘blow holes’’ to
allow the gas to escape [18,123]. Minor et al. was the ﬁrst to val-
idate that PSF might be useful for livers in a transplant setting by
infusing gaseous oxygen at 18 mmHg for 48-h at 4 C into Wistar
rat livers [124]. 48-h after PSF, the livers were reperfused in
Krebs-Henseleit buffer and were found to have dramatically
lower levels of Kupffer cell activation as compared to the non-
PSF controls when measuring acid phosphate.
PSF has also been shown to reduce cellular proteolysis in
rodent liver grafts [125]. As proteolytic activity has been associ-
ated with impaired hepatic injury, inhibition of redox reactions
can lead to inappropriate oxidation of intracellular components
[126].426 Journal of Hepatology 201Persufﬂation may rehabilitate marginal livers
Minor et al. also established that PSF or venous systemic oxygen
persufﬂation (VSOP) could be used to rehabilitate DCD livers after
30-min of cardiac arrest [127]. Transplanting these livers after
24-h of PSF, there was enhanced NADH re-oxidation, normalized
ATP concentration, and sustained ATP energy charge potential.
This decreased tissue speciﬁc NADH was measured with micro-
scopic ﬂuorescence substantiating the notion of preserved mito-
chondrial oxidative phosphorylation [128].
Remarkably, PSF was also shown to rehabilitate rat livers after
47-h of CS in UW solution. Attaching these livers to the PSF cir-
cuit for only 1-h lead to lower AST levels and conserved ATP con-
centrations after in vitro reperfusion as compared to solely CS
livers [129].
PSF was also examined in steatotic livers in a rodent model of
starvation followed by fat-free carbohydrate rich diet [130]. Reca-
pitulating moderate steatosis, PSF for 24-h lead to better main-
tained sinusoidal endothelium and mitochondria integrity.
Moreover, again AST levels were lower as well as glutamate
dehydrogenase levels, possibly reﬂecting less parenchymal dam-
age which coincided with decreased portal venous pressures
upon in vitro reperfusion.
However, while PSF has been able to sustain oxidation metab-
olism, concerns over oxidative free radical injury to stress paren-
chyma has arisen. Furthermore in a recent study, superoxide
dismutase or n-acetylcysteine in conjugation with PSF, lowered
the concentration of lipid peroxidation in DCD rodent livers
[131]. Interestingly, poorer results were seen without these
anti-oxidants, in part supporting the notion that PSF may pro-
mote a damaging oxidative milieu in ischemically challenged
grafts. After a short course of high-dose reduced glutathione, con-
comitant PSF can also protect steatotic rodent livers from ische-
mic damage after transplantation [132]. Moreover, glutathione,
a free radical scavenger was shown to reduce hepatic necrosis
in pre-treated fatty livers as compared to the non-treated arm,
and improve survival.
Nitrous oxide (NO) is yet another compound that has shown
promising results in persufﬂated livers due to its anti-oxidant
and vasodilator properties [133]. Srinivasan et al. would validate
this assertion by persufﬂating DCD rodent livers with gaseous
oxygen and 80 ppm NO via the IVC [134]. Expectedly, upon reper-
fusion, livers in the VSOP-NO arm had a decreased presence of
hepatocellular inﬂammatory markers and lower levels of mal-
ondialdehyde, an indicator of oxidative stress and lipid peroxida-
tion. In the ultimate litmus test, Yagi et al. established that VSOP-
NO partial rodent liver grafts had better regeneration metrics,
higher Ki67 expression and upregulated hepatic endothelial NO
synthase (e-NOS) [135]. e-NOS can counter endothelin-1 induced
vasoconstriction, bettering the hepatic microcirculation and les-
sen TNF-a expression [136]. VSOP-NO may also rehabilitate par-
tial liver grafts encumbered with steatosis when measuring the
usual parameters of parenchymal damage and graft viability
[137].
Larger animal models to establish the efﬁcacy of PSF in these
marginal grafts would follow with the use of a porcine system.
Again, PSF would prove to be effective in altering in hepatic injury
as measured by AST and LDH in DCD grafts [138]. Strikingly, ani-
mals transplanting with a DCD liver that did not undergo PSF all
died shortly after 3-h of reperfusion. Later it was determined that
2-h was the optimum time of PSF following CS that allowed for4 vol. 61 j 418–431
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Fig. 3. Machine perfusion devices. (A, B) Photograph of Organ Recovery Systems Inc. LifePort Liver Transporter prototype. (C) ECOPS device (Organ Assist). (D) The
OrganOx metra™ device.
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correlated with 83% 7-day survival [139,140]. Portal venous ﬂow
parameters in these reperfused grafts were also improved with 2-
h of PSF, likely representing less parenchymal edema from IRI.
Persufﬂation in the clinical setting
The early foray of PSF into the clinical setting took place in 2004
when surgeons in Germany transplanted 5 livers from DCD
donors with WITs in excess of 20-min and that had been turned
down by at least 3 centers [141]. In this pilot study, all of these
livers were persufﬂated through the IVC for at least 1-h prior to
transplantation and biopsies were taken before and after being
placed on the PSF circuit. One patient suffered from a hepatic
artery thrombosis post-operatively that resolved with thrombec-
tomy and another from a subcapsular hematoma that needed a
wash-out. ATP levels in the liver tissue post-PSF were more than
2-fold pre-PSF concentrations.
As such, in 2011 a registered human trial was started to exam-
ine in a larger cohort, 2-h of PSF in transplanted livers [142]. Pro-
spective and randomized, this single center study entitled
‘‘Oxygen persufﬂation as adjunct in liver preservation’’ (OPAL)
looks to assess the effects of 2-h of PSF and the primary outcomesJournal of Hepatology 201of peak transaminase serum levels (AST), early-onset of graft dys-
function, patient and graft survival.Technological advances in preservation
The development of newer machine perfusion devices will take a
concerted effort between medicine and industry
The development of reproducible liver machine perfusion pumps
has begun relatively recently. Taking a cue from kidney perfusion
pumps, the advent of liver machine perfusion pumps at the basic
level included an organ chamber, heat exchanger, membrane
oxygenator and a vascular circuitous pump mechanism. The
Groningen Liver Perfusion Pump was among the ﬁrst prototypes
described for large animal liver HMP [143]. Relying on a dichot-
omous oxygenated pumping system that allowed for continues
ﬂow to the portal vein (4 mmHg) and pulsatile ﬂow to the hepatic
artery (30/20 mmHg), this pump facilitated complete perfusion of
porcine livers without evident histological damage. Notably, in
earlier studies these pressures were set with regard to concerns
relating to endothelial injury. In machine perfusion livers there
arose the notion that the normally low-pressure portal venous4 vol. 61 j 418–431 427
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system would be unduly affected by small variations in pressures
seen during continuous perfusion. Particularly, ‘t Hart et al.
showed that rodent livers undergoing HMP fared better with
25% of their normothermic circulation (mean arterial perfusion
pressure of 25 mmHg and a portal perfusion pressure of 4 mmHg)
as opposed to 50% (mean arterial perfusion of 50 mmHg and
8 mmHg portal perfusion pressure) [144].
A few years later in Belgium, Monbaliu et al. described a sim-
ilar pressure-controlled and ﬂow-limited continuous perfusion
pump in a porcine model and calculated the resistance parame-
ters during perfusion [145]. Progressive arterial relaxation as
manifested by decreased vascular resistance was seen until a
steady state was reached at 6-h after initiation of HMP. Other
more recent designs included one machine perfusion systemwith
3 circulating systems for enhanced heat exchange and an oxygen-
ator of the dichotomous arterial and portal venous circuits [146].
Our current work is progressing rapidly on a more portable and
durable liver machine perfusion pump in the form of LifePort
Liver Transporter; Organ Recovery Systems (Chicago, IL) with
extensive design input from our group to insure practicality
and widespread clinical applicability (Fig. 3).Conclusion
Despite the history of mixed results with the use of marginal liv-
ers, safe utilization of these grafts holds the potential to reduce
waitlist mortality and improve access to liver transplantation.
While shorter CITs and improved donor selection is a good start,
the potential of a wide array of ex vivo interventions is now pro-
gressing into clinical application. These interventions that change
the way we practice medicine by expanding the donor pool and
improving clinical results with marginal allografts liver is excit-
ing and undeniable.
Perhaps most importantly, exciting preclinical work using
machine preservation as a platform for elaborate ex vivo inter-
ventions such as knockout of deleterious IRI genes, stem cell ther-
apy, and bio-artiﬁcial liver development have been proposed by
cutting edge innovators. Such interventions hold further promise
for ex vivo resuscitation of marginal liver allografts.Conﬂict of interest
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